昭衍新药：认购中信证券金融产品投资金额5.4亿元

南方财经网09-23 16:53

南财智讯9月23日电，昭衍新药（06127.HK）发布须予披露交易公告，于2026年4月20日至2026年9月23日期间，公司附属公司透过中信证券及其附属公司认购了七项中信证券金融产品，合计投资金额为人民币5.4亿元。（文章来源：南方财经网）

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2669910137?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-09-23 16:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2669910137","market":"us","top_or_hot":-1,"title":"昭衍新药：认购中信证券金融产品 投资金额5.4亿元","media":"南方财经网","content":"<div>\n<p>南财智讯9月23日电，昭衍新药（06127.HK）发布须予披露交易公告，于2026年4月20日至2026年9月23日期间，公司附属公司透过中信证券及其附属公司认购了七项中信证券金融产品，合计投资金额为人民币5.4亿元。（文章来源：南方财经网）</p>\n\n<a href=\"http://finance.eastmoney.com/a/202609233882481581.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>昭衍新药：认购中信证券金融产品 投资金额5.4亿元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n昭衍新药：认购中信证券金融产品 投资金额5.4亿元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-09-23 16:53 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202609233882481581.html><strong>南方财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>南财智讯9月23日电，昭衍新药（06127.HK）发布须予披露交易公告，于2026年4月20日至2026年9月23日期间，公司附属公司透过中信证券及其附属公司认购了七项中信证券金融产品，合计投资金额为人民币5.4亿元。（文章来源：南方财经网）</p>\n\n<a href=\"http://finance.eastmoney.com/a/202609233882481581.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1794554557.SGD","symbol_name":"Allianz All China Equity AT Acc H2-SGD","start_time":0,"source_url":"http://finance.eastmoney.com/a/202609233882481581.html","article_id":"2669910137","we_media_id":null,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609233882481581.html","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2669910137","pubTimestamp":1790153580,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"南财智讯9月23日电，昭衍新药（06127.HK）发布须予披露交易公告，于2026年4月20日至2026年9月23日期间，公司附属公司透过中信证券及其附属公司认购了七项中信证券金融产品，合计投资金额为人民币5.4亿元。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159940":"金融","600030":"中信证券","603127":"昭衍新药","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","BK1521":"挪威政府全球养老基金持仓","06030":"中信证券","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","LU1720050803.USD":"安联全方位中国股票基金","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","LU1146622755.USD":"安本中国A股股票基金A Acc","BK0183":"MSCI概念","BK0188":"融资融券","BK0012":"证金概念","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","BK1564":"中资券商股","BK1141":"生命科学工具和服务","BK1576":"医药外包概念","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","BK0276":"资本市场","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","BK0028":"国家队","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","LU2289578879.USD":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","LU1580142542.USD":"Blackrock Systematic China A-Share Opportunities A2 USD","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","BK1516":"腾讯概念","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","06127":"昭衍新药","LU1997245177.USD":"安联神洲A股基金","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","BK1147":"投资银行业与经纪业","BK0196":"行业龙头","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC","LU1781817850.SGD":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","BK0216":"研究试验"},"translate_title":"Joinn Laboratories: Subscribed to CITIC Securities financial products with an investment of 540 million yuan.","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159940":1.5,"600030":1.5,"603127":1.5,"06127":1.5,"06030":1.5},"content_text":"南财智讯9月23日电，昭衍新药（06127.HK）发布须予披露交易公告，于2026年4月20日至2026年9月23日期间，公司附属公司透过中信证券及其附属公司认购了七项中信证券金融产品，合计投资金额为人民币5.4亿元。（文章来源：南方财经网）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2669910137","isCrawlerRequest":true}

昭衍新药：认购中信证券金融产品 投资金额5.4亿元

精彩评论

昭衍新药：认购中信证券金融产品投资金额5.4亿元